Synthesis and Mode of Action of Hydrophobic Derivatives of the Glycopeptide Antibiotic Eremomycin and Des-(N-methyl-d-leucyl)eremomycin against Glycopeptide-Sensitive and -Resistant Bacteria
- 9 February 2002
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 45 (6) , 1340-1347
- https://doi.org/10.1021/jm010460i
Abstract
Des-(N-methyl-d-leucyl)eremomycin was obtained by Edman degradation of eremomycin. Derivatives with a hydrophobic substituent at the exterior of the molecule were then synthesized, and their antibacterial activities were compared with similar derivatives of eremomycin. Comparison of derivatives of eremomycin containing the n-decyl or p-(p-chlorophenyl)benzyl substituent in the eremosamine moiety (N‘) and n-decyl or p-(p-chlorophenyl)benzylamides with similar derivatives of eremomycin possessing the damaged peptide core (a defective binding pocket) showed that compounds of both types are almost equally active against glycopeptide-resistant strains of enterococci (GRE), whereas eremomycin derivatives are more active against staphylococci. Hydrophobic 7d-alkylaminomethylated derivatives of eremomycin (9, 10) demonstrated similar antibacterial properties. Since the basic mode of action of glycopeptide antibiotics involves binding to cell wall intermediates terminating in -d-Ala-d-Ala and this interaction is seriously decreased in the hexapeptide derivatives (lacking the critical N-methyl-d-leucine), we suggest that these hydrophobic derivatives may inhibit peptidoglycan synthesis in the absence of dipeptide binding. NMR binding experiments using Ac-d-Ala-d-Ala show that binding constants of these hexapeptide derivativies are decreased in comparison with the corresponding heptapeptides with intact binding pocket. This is in agreement with the decreased biological activity of the hexapeptide derivatives against vancomycin-sensitive strains in comparison with the activity of parent compounds. Binding to the lactate cell wall analogue Ac-d-Ala-d-Lac with decylamide of eremomycin 8 was not observed, demonstrating that the interaction with this target in GRE does not occur. While hydrophobic glycopeptide derivatives retain the ability to inhibit the synthesis of peptidoglycan in manner of natural glycopeptides, biochemical investigation supports the hypothesis that they inhibit the transglycosylase stage of bacterial peptidoglycan biosynthesis even in the absence of dipeptide or depsipeptide binding.Keywords
This publication has 15 references indexed in Scilit:
- Genetic Basis for Activity Differences Between Vancomycin and Glycolipid Derivatives of VancomycinScience, 2001
- Synthesis of Hydrophobic N'-Mono and N',N"-Double Alkylated Eremomycins Inhibiting the Transglycosylation Stage of Bacterial Cell Wall Biosynthesis.The Journal of Antibiotics, 2001
- The Role of Hydrophobic Substituents in the Biological Activityof Glycopeptide AntibioticsJournal of the American Chemical Society, 2000
- Chlorobiphenyl-desleucyl-vancomycin inhibits the transglycosylation process required for peptidoglycan synthesis in bacteria in the absence of dipeptide bindingFEMS Microbiology Letters, 2000
- Structure-Activity Relationships in the Series of Eremomycin Carboxamides.The Journal of Antibiotics, 2000
- Structural modifications of glycopeptide antibioticsMedicinal Research Reviews, 1997
- A New Type of Chemical Modification of Glycopeptides Antibiotics: Aminomethylated Derivatives of Eremomycin and Their Antibacterial Activity.The Journal of Antibiotics, 1997
- Thermodynamics and kinetics of dissociation of ligand-induced dimers of vancomycin antibioticsJournal of the Chemical Society, Faraday Transactions, 1997
- Activities of the semisynthetic glycopeptide LY191145 against vancomycin-resistant enterococci and other gram-positive bacteriaAntimicrobial Agents and Chemotherapy, 1995
- An NMR study of eremomycin and its derivatives.The Journal of Antibiotics, 1991